82 related articles for article (PubMed ID: 17448679)
41. Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml.
Wiebe E; Rodrigues G; Lock M; D'Souza D; Stitt L
Can J Urol; 2008 Jun; 15(3):4078-83. PubMed ID: 18570713
[TBL] [Abstract][Full Text] [Related]
42. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
Connolly D; Black A; Gavin A; Keane PF; Murray LJ
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
[TBL] [Abstract][Full Text] [Related]
43. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases.
Fleischmann A; Schobinger S; Schumacher M; Thalmann GN; Studer UE
Prostate; 2009 Mar; 69(4):352-62. PubMed ID: 19016478
[TBL] [Abstract][Full Text] [Related]
44. Tumor length in prostate cancer.
Vollmer RT
Am J Clin Pathol; 2008 Jul; 130(1):77-82. PubMed ID: 18550474
[TBL] [Abstract][Full Text] [Related]
45. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.
Nguyen PL; Chen MH; Catalona WJ; Moul JW; Sun L; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):659-64. PubMed ID: 18692327
[TBL] [Abstract][Full Text] [Related]
46. Concordance of survival in family members with prostate cancer.
Hemminki K; Ji J; Försti A; Sundquist J; Lenner P
J Clin Oncol; 2008 Apr; 26(10):1705-9. PubMed ID: 18375899
[TBL] [Abstract][Full Text] [Related]
47. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
48. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
49. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE.
Ryan CJ; Elkin EP; Cowan J; Carroll PR
Cancer; 2007 Jul; 110(1):81-6. PubMed ID: 17516446
[TBL] [Abstract][Full Text] [Related]
50. Determinants of prostate cancer stage in northern New England: USA Franco-American contextual effects.
Parsons MA; Askland KD
Soc Sci Med; 2007 Nov; 65(10):2018-30. PubMed ID: 17689162
[TBL] [Abstract][Full Text] [Related]
51. [Spatial accumulation of mortality and morbidity from cancer of the prostate (ICD-10:C61)].
Siller G; Páldy A; Nádor G; Vincze I; Zsámbokiné MB; Rajcsányi A; Pintér A
Magy Onkol; 2002; 46(2):131-7. PubMed ID: 12202892
[TBL] [Abstract][Full Text] [Related]
52. Conservative treatment of prostate cancer.
Barry HC
J Fam Pract; 1996 Mar; 42(3):224, 226. PubMed ID: 8636669
[No Abstract] [Full Text] [Related]
53. What can geography tell us about prostate cancer?
Klassen AC; Platz EA
Am J Prev Med; 2006 Feb; 30(2 Suppl):S7-15. PubMed ID: 16458793
[TBL] [Abstract][Full Text] [Related]
54. Effects of study area size on geographic characterizations of health events: prostate cancer incidence in Southern New England, USA, 1994-1998.
Gregorio DI; Samociuk H; DeChello L; Swede H
Int J Health Geogr; 2006 Feb; 5():8. PubMed ID: 16480512
[TBL] [Abstract][Full Text] [Related]
55. Nonparametric estimation of the concordance correlation coefficient under univariate censoring.
Guo Y; Manatunga AK
Biometrics; 2007 Mar; 63(1):164-72. PubMed ID: 17447941
[TBL] [Abstract][Full Text] [Related]
56. Breast cancer surveillance using gridded population units, Connecticut, 1992 to 1995.
Gregorio DI; Samociuk H
Ann Epidemiol; 2003 Jan; 13(1):42-9. PubMed ID: 12547484
[TBL] [Abstract][Full Text] [Related]
57. Geographic variation in the treatment of prostate cancer in Connecticut.
Polednak AP
Int J Technol Assess Health Care; 1993; 9(2):304-10. PubMed ID: 8458708
[TBL] [Abstract][Full Text] [Related]
58. [Prognosis of prostate cancer].
Rannikko S
Duodecim; 1982; 98(4):258-66. PubMed ID: 7084087
[No Abstract] [Full Text] [Related]
59. Geographical clustering of prostate cancer grade and stage at diagnosis, before and after adjustment for risk factors.
Klassen AC; Kulldorff M; Curriero F
Int J Health Geogr; 2005 Jan; 4(1):1. PubMed ID: 15649329
[TBL] [Abstract][Full Text] [Related]
60. Subject loss in spatial analysis of breast cancer.
Gregorio DI; Cromley E; Mrozinski R; Walsh SJ
Health Place; 1999 Jun; 5(2):173-7. PubMed ID: 10670998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
